Deciphera Pharmaceuticals, Inc. announced that it has initiated an open-label, multicenter, Phase 1b/2 study of rebastinib, the company’s investigational small molecule switch control inhibitor of TIE2 kinase, in combination with carboplatin in patients with advanced or metastatic solid tumors.